NICE turns down GSK’s IV Benlysta for systemic lupus
The cost watchdog said uncertain trial evidence and cost-effectiveness estimates are behind the preliminary decision
Read More
Tag: Benlysta
EC clears GSK’s Benlysta for lupus nephritis
The drug is the only biologic treatment approved in Europe that is specifically designed to work in systemic lupus erythematosus and lupus nephritis
Read More
GlaxoSmithKline wins Benlysta US label expansion for children
The approval marks the first medicine in the US approved for children with systemic lupus erythematosus.
Read More
GSK trials Benlysta/rituximab combo for lupus
GlaxoSmithKline has kicked off a Phase III trial assessing its lupus drug Benlysta in combination with rituximab in adult patients with the condition.
Read More
EU approves subcutaneous form of GSK’s Benlysta
A new subcutaneous formulation of GlaxoSmithKline’s Benlysta has been approved as an add-on therapy for certain in adults with the autoimmune disease systemic lupus erythematosus (SLE).
Read More
GSK confirms departure of R&D chief
Ending days of speculation GlaxoSmithKline has now confirmed the departure of its current R&D chief Patrick Vallance. The drugs giant has also presented new data for lupus drug Benlysta.
Read More
GSK files for extended use of Relvar Ellipta in asthma
GlaxoSmithKline and Innoviva have applied to market Relvar Ellipta for extended use in patients with asthma who are already adequately controlled on inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy.
Read More
GSK’s Benlysta shows sustained disease control in study
Adding GSK’s Benlysta to standard of care in patients with lupus prolonged control of disease activity, according to newly-released findings of a 10-year continuation study.
Read More
Three new medicines cleared for use by NHS Scotland
The Scottish Medicines Consortium has endorsed three medicines for routine use by NHS Scotland, offering new options to treat a rare eye disease, lupus and infertility.
Read More
GSK files for approval of subcutaneous lupus drug
GlaxoSmithKline has filed for approval of a subcutaneous formulation of its lupus drug Benlysta on both sides of the Atlantic.
Read More
Final NICE nod for GSK’s lupus drug Benlysta
Within the next three months patients with lupus should get ‘routine’ access to a new treatment option on the NHS in England and Wales after cost regulators issued final guidance for GlaxoSmithKline’s Benlysta.
Read More
Subcutaneous form of GSK lupus drug on target
GlaxoSmithKline has presented promising late-stage data on a subcutaneous formulation of its lupus drug Benlysta in a subset of patients with highly-active forms of the disease.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
